Overpatented, Overpriced: Lantus

95% of the patent applications on the diabetes drug Lantus
(insulin glargine) were filed after the drug was on the market.
Read our 2018 report to find out more.

Read the 2018 Report

Partner with us now to build
a more just and equitable
medicine system for all.